Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2016, H&D Asset Management Co., Ltd. is based in Taipei, Taiwan. The firm specializes in early-stage and pre-IPO investments, primarily in the digital and biotechnology sectors. They operate as Limited Partners in Venture Capital and also engage in various securities trading markets.
H&D Asset Management invests in healthcare, biotechnology, AI, cybersecurity, and Web 3.0 sectors. They support early-stage research and clinical trials aimed at improving human health, with investments spanning across Asia, the United States, Europe, and India. Typical investment stages include Seed, Series A, Series B, and Pre-IPO.
Notable portfolio companies include Cybavo, acquired by Circle in 2022; Graid, which develops IT storage infrastructure solutions; Photoneo, specializing in 3D industrial sensors; BlossomHill Therapeutics, Inc., focused on oncology drug discovery; ClearMind, which develops solutions for intracerebral hemorrhage; and Renxin Pharmaceuticals, conducting a phase 3 clinical trial for Stargardt disease.
Submit through their form at http://www.hndasset.com.
Yes, H&D Asset Management often leads investment rounds, particularly in their focus sectors.
The firm is open to follow-on investments, especially for companies that demonstrate significant growth potential and align with their investment thesis.
Specific fund size details are not publicly available, but the firm actively manages investments across multiple sectors.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.